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Recent studies have shown that some drugs that are not routinely used to treat fungal
infections have antifungal activity, such as protease inhibitor antiretroviral drugs. This study
investigated the in vitro susceptibility of Histoplasma capsulatum var. capsulatum to saquinavir
and  ritonavir, and its combination with the antifungal itraconazole. The susceptibility assay
was performed according to Clinical and Laboratory Standards Institute guidelines. All
strains were inhibited by the protease inhibitor antiretroviral drugs. Saquinavir showed min-
imum  inhibitory concentrations ranging from 0.125 to 1 g mL−1 for both phases, and riton-
avir  presented minimum inhibitory concentrations ranging from 0.0312 to 4 g mL−1and
from  0.0625 to 1 g mL−1 for ﬁlamentous and yeast phase, respectively. Concerning the anti-
fungal itraconazole, the minimum inhibitory concentration values ranged from 0.0019 to
0.125 g mL−1 and from 0.0039 to 0.0312 g mL−1 for the ﬁlamentous and yeast phase, respec-
tively.  The combination of saquinavir or ritonavir with itraconazole was synergistic against
H.  capsulatum,  with a signiﬁcant reduction in the minimum inhibitory concentrations of bothdrugs against the strains 
protease inhibitors and it
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Introduction
Histoplasmosis is a systemic infection caused by the dimor-
phic fungus Histoplasma capsulatum. It is mainly associated
with immunosuppression, especially in HIV patients.1,2 This
disease is characterized by a broad spectrum of clinical
manifestations ranging from asymptomatic to dissemi-
nated forms.3 Histoplasmosisis is widely distributed in the
Americas.4 In Brazil, the number of cases has increased in
several regions. Some outbreaks have been recorded in the
country, involving the states of Rio de Janeiro, São Paulo, Minas
Gerais, Espírito Santo, Mato Grosso, and Rio Grande do Sul.4–6
In Ceará state, a recent study reported 254 cases of histoplas-
mosis in patients with HIV in the period from 2006 to 2010,
showing its high prevalence in this region.7
Treatment of histoplasmosis depends on the severity of
infection, clinical manifestations and individual risk factors.
The therapy indicated for mild to moderate cases is the
administration of azoles, such as itraconazole. The use of
amphotericin B is limited to severe cases because of its high
toxicity. Due to the increase of histoplasmosis cases in recent
years, particularly among HIV patients, associated with the
occurrence of refractory and recurrent infections, there is
a need to ﬁnd new therapeutic approaches to control this
mycosis.8,9 Some studies have shown that certain drugs not
routinely used to treat fungal infections have signiﬁcant anti-
fungal activity.10 Among these, the antiretroviral drugs have
demonstrated the ability to interfere with the viability and vir-
ulence of fungal cells. The protease inhibitors indinavir and
ritonavir have shown in vitro and in vivo inhibitory effects
against Candida albicans.11 Indinavir also has shown activity
against the fungus Cryptococcus neoformans, reducing its viru-
lence and making it more  susceptible to the killing activity of
natural effector cells of the immune system.12
Thus, this study aimed to evaluate the in vitro susceptibil-
ity of H. capsulatum var. capsulatum to the antiretroviral drugs
saquinavir and ritonavir, as well as their combination with the
azole antifungal itraconazole.
Materials  and  methods
Microorganisms
We  used a total of 20 clinical strains of H. capsulatum in the ﬁl-
amentous phase and 10 in the yeast phase, isolated from the
Northeast and Southeast regions of Brazil. The samples came
from the culture collection of the Specialized Medical Mycol-
ogy Center, Federal University of Ceará, and were handled in
a biosafety level 3 cabin.
Antifungal  agents
Stock solutions of the antiretroviral drugs saquinavir (Roche
Holding AG, Basel, Switzerland) and ritonavir (Abbott Labora-
tories, Chicago, USA) and the antifungal itraconazole (Janssen
Pharmaceutica, Beerse, Belgium) were prepared in dimethyl
sulfoxide (DMSO). These solutions were stored at −20 ◦C
until use. Serial dilutions of each antimicrobial agent were 1 6;2  0(2):155–159
prepared in RPMI 1640 (Sigma Chemical Corporation, St. Louis,
MO, USA), supplemented with l-glutamine, buffered at a pH
of 7.0 with MOPS 165 mmol  l−1 (Sigma Chemical Corporation,
St. Louis, MO, USA).
Preparation  of  fungal  inoculum
To prepare the inoculum, fungal suspensions were prepared
in saline from stock cultures after seven days of incubation,
maintained on BHI (brain heart infusion) agar and incubated
at 28 ◦C for the ﬁlamentous phase. The cultures were main-
tained on BHI agar supplemented with sheep blood at 10% and
incubated at 35 ◦C to obtain the yeast phase. The inoculum
was adjusted to 90–95% by transmittance spectrophotometry
at a wavelength of 530 nm.  After reading, the suspensions
were diluted 1:10 in RPMI 1640 medium to obtain inoculums
of approximately 0.5 × 103 to 2.5 × 104 cfu mL−1.13
Susceptibility  test
The in vitro antifungal activity was determined by the
broth microdilution method in accordance with the pro-
tocol described in document M27-A3 and standardized by
the Clinical Laboratory Standards Institute.14 Initially, the
minimum inhibitory concentration (MIC) was determined
for each drug. Subsequently, the MIC values were used
as the highest concentration to prepare drugs in com-
bination. The concentration ranges of the drugs alone
were: 0.0039–2 g mL−1 for saquinavir, 0.0156–8 g mL−1 for
ritonavir, and 0.0009–0.5 g mL−1 for itraconazole. The con-
centration ranges of the drugs in combination were:
0.0002–1 g mL−1 for saquinavir, 0.00006–4 g mL−1 for riton-
avir and 0.000003–0.0625 g mL−1 for itraconazole. The results
were determined by visual readings after seven and four
days of incubation at 35 ◦C for strains in the ﬁlamentous and
yeast phase, respectively. The MICs were deﬁned as the low-
est concentration of drug able to inhibit 80% of the fungal
growth for antiretroviral drugs and itraconazole, as well as
for the combination of both.13 Drug interaction was evaluated
by calculating the fractional inhibitory concentration index
(FICI), which was classiﬁed as synergistic (FICI ≤ 0.5), indiffer-
ent (0.5 < FICI < 4), or antagonistic (FICI ≥ 4).15 The FICI values
obtained for each drug combination against H. capsulatum
were compared through Wilcoxon test (p < 0.05). The analy-
sis was carried out using IBM SPSS ver. 21.0 software (IBM
Co., Armonk, NY, USA). Standard strains of Candida parapsilo-
sis ATCC 22019 and Candida krusei ATCC 6258 were included in
each test as quality controls.
Results
The protease inhibitors saquinavir and ritonavir were capa-
ble of inhibiting the strains of H. capsulatum,  with MIC values
ranging from 0.125 to 1 g mL−1 for saquinavir in both ﬁla-
−1mentous and yeast phase; and from 0.0312 to 4 g mL and
from 0.0625 to 1 g mL−1 for ritonavir in ﬁlamentous and yeast
phase, respectively (Table 1). Concerning itraconazole, the
MIC ranged from 0.0019 to 0.0625 g mL−1 and from 0.0039 to
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Table 1 – MICs of antiretroviral drugs and itraconazole against strains of Histoplasma capsulatum var. capsulatum in
yeast-like and mycelial forms.
Strains Saquinavi (g mL−1) Ritonavir (g mL−1) Itraconazole (g mL−1)
Mycelial form
0.125  (2)a 0.0312 (1) 0.0019 (2)
0.25 (6) 0.125 (1) 0.0078 (4)
0.5 (8) 0.5 (4) 0.0156 (6)
1 (4) 1 (5) 0.0312 (6)
2 (5) 0.0625 (2)
4 (4)
Yeast form
0.125  (3) 0.0625 (4) 0.0039 (1)
0.25 (1) 0.125  (3) 0.0078  (4)
0.5 (4) 0.5  (2) 0.0156  (2)
1 (2) 1  (1) 0.0312  (3)
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.0312 g mL−1 for the ﬁlamentous and yeast phase, respec-
ively (Table 1).
Synergistic interactions were observed for the combi-
ations of saquinavir or ritonavir with itraconazole, and
here was a signiﬁcant reduction in the MIC of these drugs:
aquinavir (p = 0.0000) and itraconazole (p = 0.0000) for ﬁla-
entous and yeast phases; and ritonavir (p = 0.0001) and
traconazole (p = 0.0003) for ﬁlamentous phase and riton-
vir (p = 0.0297) and itraconazole (p = 0.0015) for yeast phase
Table 2). No antagonistic interactions were observed.
iscussion
n recent years, studies have shown that HIV patients can have
ubstantially longer life expectancy, depending on adherence
o antiretroviral treatment and the evolution of the immune
tatus. Also, the use of more  effective therapy decreases the
ncidence of opportunistic infections, including histoplasmo-
is. Even though the use of protease inhibitors, including
aquinavir, has been associated with the development of
everal side effects, recent studies have demonstrated that
he use of liposome saquinavir formulations signiﬁcantly
ecreases the levels of cytotoxicity, besides improving the
ioavailability of this drug.16Moreover, it has been observed that the protease inhibitors
an have beneﬁcial effects on some fungal infections, not only
y modulating the immune system of the susceptible host,
ut also by exerting direct action against the pathogen.17 It
Table 2 – Effects of the combination of antiretroviral drugs and 
yeast-like and mycelial forms.
Strains Drugs MIC–geometric mean
(isolated drugs)
MIC–geomet
(combined
Antiretroviral Antifungal Antiretroviral 
Mycelial
form
SAQ/ITC 0.4 0.01 0.002 
RIT/ITC 1.03 0.01 0.27 
Yeast
form
SAQ/ITC 0.45 0.01 0.02 
RIT/ITC 0.15 0.01 0.01 
SAQ = saquinavir; RIT = ritonavir; ITC = itraconazole; S = synergistic interacthas also been observed from in vitro and in vivo studies that
protease inhibitors reduce the pathogenicity and growth of C.
albicans probably because these drugs act directly on the pro-
duction of the enzyme aspartyl-proteinases, which is secreted
by this organism in the processes of invasion and colonization
of host tissues.18–20 Additionally, it has been shown that riton-
avir inhibits the in vitro hyphal growth rate of C. albicans,21
ritonavir and saquinavir inhibit the adherence of C. albicans
to endothelial cells,22 and saquinavir, ritonavir, and indinavir
attenuate the in vitro adherence of C. albicans to acrylic sub-
stances, which is a common component of oral appliances.23
More recently, it was observed that the protease inhibitors
saquinavir, darunavir, ritonavir, and indinavir did not reduce
the in vitro growth of C. neoformans,  but reduced protease activ-
ity as well as capsule production, important virulence factors
of C. neoformans.24 Although there are some studies on the
action of protease inhibitors against fungi, no reports for H.
capsulatum have been published so far.
In the present study, we observed that the protease
inhibitors saquinavir and ritonavir alone inhibited H. capsu-
latum,  and saquinavir and ritonavir interacted synergistically
with itraconazole, as evidenced by the increased in vitro activ-
ity of the antifungal drug. The advantage of the synergistic
effect of the combination of antiretroviral and antifungal
drugs aims to attenuate toxic effects caused by them, espe-
cially in cases of long-term therapies, such as in HIV-infected
patients presenting with histoplasmosis.2
Casolari et al.25 found that saquinavir alone did not show
signiﬁcant antifungal activity against the yeast forms of C.
itraconazole on strains of H. capsulatum var. capsulatum in
ric mean
 drugs)
FICI geometric
mean
Results Number of strains
presenting synergism
Antifungal
0.0001 0.007 S 20/20
0.004 0.5 S 13/20
0.001 0.12 S 10/10
0.001 0.16 S 10/10
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albicans and C. neoformans. However, when combined with the
azole drug ﬂuconazole, it was found to inhibit the growth of
these fungal species, indicating the occurrence of synergism
between the drugs. Similarly, Palmeira et al.26 described the
effect of nelﬁnavir and saquinavir against the dematious fun-
gus Fonsecaea pedrosoi and conﬁrmed that these compounds
alone were unable to inhibit the growth of this fungus.
However, inhibition did occur when sub-inhibitory doses of
these protease inhibitors were combined with amphotericin
B. Mikus et al.27 noted that ritonavir prolongs the clearance of
voriconazole, although the use of ritonavir with voriconazole
is contraindicated because the former lowers the plasma
levels of voriconazole.
Our data demonstrated an in vitro synergistic interaction
between saquinavir or ritonavir with itraconazole against the
dimorphic fungus H. capsulatum. The mechanism underlying
the observed synergy remains unknown, but Crommentuyn
et al.28 showed that the in vivo combination of antiretroviral
lopinavir/ritonavir and itraconazole interacts through phar-
macokinetic pathways, interfering with the metabolism of the
antifungal drug, which increases the plasma level of the anti-
fungal agent, thus, making it possible to reduce the dosage of
itraconazole without impairing the treatment. Based on our
ﬁndings, we  believe that saquinavir or ritonavir with itracona-
zole interact probably through pharmacodynamic pathways.
These data show an important in vitro synergy between
saquinavir or ritonavir and itraconazole against the fungus H.
capsulatum, which is an important pathogen for AIDS patients.
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